Efficacy & safety of genetically engineered chondrocytes with TGF-β1 vs placebo in knee OA .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee
Osteoarthritis Cartilage. 2015 Dec;23(12):2109-18.102 patients with grade III (Kellgren-Lawrence) knee osteoarthritis were randomized to intra-articular injection administration of either genetically engineered chondrocytes expressing TGF-b1 (GEC-TGF-b1; TissueGene-C; TissueGene Inc.) or placebo. The purpose of this study was to evaluate the efficacy and safety of the GEC-TGF-b1 investigational product. Primary outcomes for function and pain (IKDC subjection and visual analog scale, respectively) demonstrated significantly greater improvement in the GEC-TGF-b1 group compared to the placebo group at 12 and 52 weeks post-injection, but not at 4 and 24 weeks post-injection. Secondary outcomes of function and quality of life did not significantly differ between groups. Adverse events occurred in 87% of the GEC-TGF-b1 group and 77% of the placebo group. Majority of AEs in the GEC-TGF-b1 group were of moderate severity and deemed at least possibly related to treatment. Most common AEs in the GEC-TGF-b1 were joint inflammation, arthralgia, and effusion
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
